Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL1008)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Dok Hyun | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Jeong, Seong Hyun | - |
dc.contributor.author | Shin, Dong-Yeop | - |
dc.contributor.author | Bae, Sung Hwa | - |
dc.contributor.author | Hong, Junshik | - |
dc.contributor.author | Park, Seong Kyu | - |
dc.contributor.author | Yhim, Ho-Young | - |
dc.contributor.author | Yang, Deok-Hwan | - |
dc.contributor.author | Lee, Hyewon | - |
dc.contributor.author | Kang, Hye Jin | - |
dc.contributor.author | Lee, Mark Hong | - |
dc.contributor.author | Eom, Hyeon-Seok | - |
dc.contributor.author | Kwak, Jae-Yong | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Suh, Cheolwon | - |
dc.contributor.author | Kim, Won Seog | - |
dc.date.accessioned | 2021-08-11T16:24:31Z | - |
dc.date.available | 2021-08-11T16:24:31Z | - |
dc.date.issued | 2016-12-20 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/8461 | - |
dc.description.abstract | We designed a new treatment protocol incorporating concurrent administration of L-asparaginase (to reduce the probability of systemic progression during concurrent chemoradiotherapy (CCRT)) plus high-dose methotrexate to consolidation chemotherapy to intensify the regimen for treating localized extranodal NK/T cell lymphoma, nasal type (ENKTL). CCRT comprised radiation (36-44 Gy) with weekly cisplatin (30 mg/m(2)) and tri-weekly L-asparaginase (4 000 IU). Chemotherapy MIDLE (methotrexate 3 g/m(2) on day 1, etoposide 100 mg/m(2) and Ifosfamide 1 000 mg/m(2) on days 2-3, dexamethasone 40 mg on days 1-4, and L-asparaginase 6 000 IU/m(2) on days 4, 6, 8, 10)-was repeated every 28 days for two cycles. One of the 28 patients developed distant lesions after CCRT. The final complete response rate was 82.1%. Four patients dropped out during or after their first MIDLE cycle due to toxicities (recurrent G3 hyperbilirubinemia [n = 1], G3-5 increased creatinine [n = 2], and G5 infection [n = 1]). With a median follow-up of 46 months (95% CI: 39-47 months), the estimated 3-year progression-free survival rate and overall survival rate were 74.1% and 81.5%, respectively. This MIDLE protocol may be effective for localized ENKTL. However, concurrent administration of L-asparaginase during CCRT does not seem to provide additional benefits. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Impact Journals | - |
dc.title | Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL1008) | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.18632/oncotarget.11319 | - |
dc.identifier.scopusid | 2-s2.0-85007502831 | - |
dc.identifier.wosid | 000391353200144 | - |
dc.identifier.bibliographicCitation | Oncotarget, v.7, no.51, pp 85584 - 85591 | - |
dc.citation.title | Oncotarget | - |
dc.citation.volume | 7 | - |
dc.citation.number | 51 | - |
dc.citation.startPage | 85584 | - |
dc.citation.endPage | 85591 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | BARR-VIRUS DNA | - |
dc.subject.keywordPlus | RETROSPECTIVE ANALYSIS | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordPlus | SMILE | - |
dc.subject.keywordAuthor | extranodal NK/T-cell lymphoma | - |
dc.subject.keywordAuthor | nasal type | - |
dc.subject.keywordAuthor | concurrent chemoradiotherapy | - |
dc.subject.keywordAuthor | L-asparaginase | - |
dc.subject.keywordAuthor | methotrexate | - |
dc.subject.keywordAuthor | treatment | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.